The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Intrapatient correlation of clinical benefit from VEGF and mTOR inhibition in metastatic renal cell carcinoma.
G. Ratnayake
No relevant relationships to disclose
A. Pender
No relevant relationships to disclose
L. M. Pickering
No relevant relationships to disclose
M. E. Gore
No relevant relationships to disclose
J. M. G. Larkin
No relevant relationships to disclose